Status:
COMPLETED
Theranostic Implication of Complementary Medicines Against Interleukin Receptors and Gp-130 Proteins
Lead Sponsor:
University of Lahore
Conditions:
Corona Virus Disease 2019 (COVID-19)
Eligibility:
All Genders
Phase:
NA
Brief Summary
IL-6 is an inflammatory marker, secrete by the cells in many pathological conditions like COVID-19 pneumonia. Interleukin 6 bind with its receptors (IL-6R) on cells surface and recruited a protein for...
Eligibility Criteria
Inclusion
- Admitted diagnosed cases of COVID-19 infection on real time polymerase chain reaction (RT-PCR) Both male and female were included All participants were on oxygen therapy
Exclusion
- Asthmatics pulmonary fibrosis chronic obstructive pulmonary disease (COPD) Allergic to remdesivir Allergic to Actemra Refused to take consent
Key Trial Info
Start Date :
July 23 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 10 2020
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT04690920
Start Date
July 23 2020
End Date
December 10 2020
Last Update
December 31 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The University of Lahore
Lahore, Punjab Province, Pakistan, 54000